Navigation Links
TriLink BioTechnologies, Inc. Announces Sales and License Agreement With Glen Research Corporation for CleanAmp(TM) Amidites
Date:6/24/2009

SAN DIEGO, June 24 /PRNewswire/ -- TriLink BioTechnologies (TriLink), announced that it has signed a sales and license agreement with Glen Research Corporation to sell TriLink's CleanAmp(TM) Amidites. Glen Research can now sell the patented CleanAmp(TM) Amidites produced by TriLink to third parties for use in the production of CleanAmp(TM) Primers.

TriLink's CleanAmp(TM) technology offers a less expensive approach to high stringency PCR. CleanAmp(TM) is a unique solution, where the primer or dNTP components of the PCR reaction mix, rather than the enzymes are modified. Making the CleanAmp(TM) Amidites available through Glen Research allows institutions with oligonucleotide synthesis capabilities to manufacture CleanAmp(TM) Primers in-house. Learn more at www.trilinkbiotech.com/cleanamp.

"Glen Research is dedicated to bringing the very best research products to the oligonucleotide synthesis market. So we are delighted to be able to offer CleanAmp(TM) Amidites in partnership with TriLink. We feel that the CleanAmp(TM) Amidites will make an excellent addition to our repertoire of products for DNA research," said Glen Research President/CEO, Dr. Hugh Mackie.

"TriLink and Glen Research have a long standing relationship built on a shared interest in advancing science through the highest quality reagents and technical expertise. We feel Glen Research is the perfect partner for bringing CleanAmp(TM) Amidites to the marketplace," said TriLink CEO, Dr. Richard Hogrefe.

About TriLink

TriLink Biotechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp(TM) PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered. TriLink's solutions help advance drug discovery and biomedical research. Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 90 scientists and other professionals. For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at http://www.trilinkbiotech.com. For more information contact:

    TriLink BioTechnologies
    Shawna Leaver, 858-546-0004
    sleaver@trilinkbiotech.com

About Glen Research

Glen Research offers a wide range of phosphoramidites and solid supports for the chemical synthesis, modification, labelling and purification of DNA and RNA oligonucleotides. Glen Research's products support the development of novel strategies for use in diagnostics, sequencing and therapeutics. Founded in 1987, Glen Research is a privately held firm based in Sterling, Virginia. For more information about the firm and products, call 703-437-6191, email support@glenres.com, or visit our web site at http://www.glenres.com.


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AFIT Accelerated Flight & Instrument Training Announces New Accelerated Flight Training Programs For Cirrus Aircraft Equipped With New Perspective Avionics by Garmin (CSIP)
2. BD Announces CE Marking of BD ProbeTec™ Qx Amplified Assays to Improve Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
3. Hanger Orthopedic Group, Inc. Announces Second Quarter 2009 Earnings Release Conference Call
4. Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings
5. Atlantic Pharmaceuticals, Inc. Announces Completion of Successful Pre-IND Meeting with FDA for Abuse Deterrent Narcotic
6. Go Healthy Announces Association With Business Development Firm
7. New York City Chiropractor Announces New State-Of-The-Art Facility, Website
8. Cogdell Spencer Announces Chief Executive Officer Frank C. Spencer Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Winner in the Carolinas
9. Microsoft Announces Winners of the 2009 Pharmaceutical and Life Sciences Innovation Awards
10. Cadence Pharmaceuticals Announces Appointment of Scott Byrd as Chief Commercial Officer
11. China Pharma Holdings, Inc. Announces SFDA Approval for Rosuvastatin Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... KS (PRWEB) , ... June 27, 2016 , ... TopConsumerReviews.com ... retailers of Eyeglasses . , Millions of individuals in the United States and ... have become a way to both correct vision and make a fashion statement. Even ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: